Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.42 |
| ▸ | ADH1C | P00326 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.42 |
| ▸ | ADH4 | P08319 | 1/20 | 0.42 |
| ▸ | ADH7 | P40394 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684384 | 0.78 | EPHX1 (0.52) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL9781816 | 0.76 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL11868180 | 0.76 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL7435302 | 0.75 | EPHX1 (0.58) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL25272490 | 0.74 | EPHX1 (0.61) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL25229374 | 0.74 | EPHX1 (0.61) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL25271573 | 0.74 | EPHX1 (0.61) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL25226017 | 0.74 | EPHX1 (0.61) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL9623877 | 0.74 | EPHX1 (0.61) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL25271060 | 0.74 | EPHX1 (0.61) | EPHX1ZDHHC20ZDHHC2CASP2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| EP-1804805-A4 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | UNIV WAYNE STATE (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080045484-A1 | Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus | MOUNT SINAI HOSPITAL (CA) | 2008-02-21 | — | — | US | disclosed |
| US-20080025991-A1 | Use of Aromatase Inhibitors for Treatment of Ectopic Pregnancy | MOUNT SINAI HOSPITAL (CA) | 2008-01-31 | — | — | US | disclosed |
| EP-1804819-A4 | USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL THINNING IN PREPARATION FOR SURGICAL PROCEDURES ON THE ENDOMETRIAL CAVITY AND UTERUS | UNIV WAYNE STATE (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1804805-A2 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | WAYNE STATE UNIVERSITY (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1804819-A2 | USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL THINNING IN PREPARATION FOR SURGICAL PROCEDURES ON THE ENDOMETRIAL CAVITY AND UTERUS | WAYNE STATE UNIVERSITY (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006041939-A2 | USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL THINNING IN PREPARATION FOR SURGICAL PROCEDURES ON THE ENDOMETRIAL CAVITY AND UTERUS | WAYNE STATE UNIVERSITY (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006041941-A2 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | WAYNE STATE UNIVERSITY (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045484-A1 | Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus | CYP19A1, SHBG, HSD17B11 | EPHX1 1711/4885ZDHHC20 2900/4885ZDHHC2 3332/4885 |
| US-20080025991-A1 | Use of Aromatase Inhibitors for Treatment of Ectopic Pregnancy | CYP19A1, HSD17B11, CYP17A1 | EPHX1 75/4885ZDHHC20 2048/4885ZDHHC2 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.